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The Surveillance, Epidemiology and End Results database is designed to provide ageneralized cross-section of cancer care in the United States. It is increasingly being
used to study patterns of care and how they relate to outcomes. This approach is an avenue
of research that will certainly play a greater role in the future. Instead of a tightly
controlled prospective study in a limited and highly selected cohort of patients, this avenue
explores relationships in a completely uncontrolled, but very large group of patients. The
fact that the results can be generalized, by definition, and the large number of patients
involved overcomes to a large extent the limitations of incomplete data, and the fact that
the reasons for changes in the patterns of care can usually not be clearly identified.
In this edition of the Journal of Thoracic Oncology, Farjah et al.1 have analyzed
staging interventions for non-small cell lung cancer (NSCLC) using the Surveillance,
Epidemiology and End Results database, linked to the medicare database. The study
encompasses almost 44,000 patients over age 65 who were diagnosed with NSCLC from
1998 to 2002 with follow-up extending through 2005. Fifty percent of the patients were
age 75, and 50% had a comorbidity index of 0. Only 23% were over age 80, and only
21% had a comorbidity index 2. No treatment was given to 27%, and 51% had either
stage IV disease or had incomplete staging information. Therefore, at least half of the
study cohort can be reasonably assumed to be candidates for standard curative therapy,
and only about 25% were likely poor or marginal candidates for standard therapy.
The study investigated whether patients had only single modality staging (radio-
graphic, i.e., chest computed tomography), bimodality staging (radiographic plus either
metabolic or positron emission tomography [i.e., positron emission tomography, or PET]
or invasive staging), or trimodality staging (radiographic, metabolic and invasive) within
3 months of the diagnosis (before or after). Most of patients underwent only single
modality staging, although the incidence of this decreased from 90 to 67% during the
course of the study. There was a corresponding increase in the proportion undergoing
bimodality staging (from 10 to 30%), which was almost exclusively due to an increase in
the use of PET (from 2 to 31%). Invasive staging was used in 10% of patients and did
not change significantly during the course of the study. Exclusion of patients for whom
extensive staging may have been inappropriate did not substantially affect these results
(i.e., patients who were stage IV, died within 30 days, or were not treated). Furthermore,
the predominance of limited staging was seen broadly and not markedly concentrated
among patients who were older (80) or had multiple comorbidities.
The study by Farjah et al. therefore, suggests that we have a major problem with the
quality of staging in the United States. Radiographic staging alone has been shown to be
inaccurate in many instances in patients with NSCLC. Even though guidelines with
respect to PET scanning were not available at the beginning of the study, the data at the
time justified the use of invasive staging in the majority of stage II and III patients. It is
astonishing just how widespread the practice of limited staging was in this study, but in
fact a similar degree of poor quality of staging for NSCLC has been reported by others as
well.2,3 The correlation of poor staging with such factors as socioeconomic status, level of
education, marital status, and geographic region is consistent with other reports associ-
ating such factors with therapeutic interventions in patients with lung cancer.4,5 Together,
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these reports suggest that attitudes and access are the greater
determinants of the care received, rather than clinical factors
that impact the appropriateness of greater levels of care.
Farjah et al. are the first to provide evidence that poor
staging leads to poor outcomes in patients with NSCLC.
Mortality was markedly and statistically highly significantly
decreased in patients undergoing bi- and tri-modality staging
(hazard ratio of 0.56 and 0.49 respectively, after adjustment
for age, comorbidity, demographic, and socioeconomic fac-
tors). Stated differently, the chance of dying was approxi-
mately cut in half among the patients with more extensive
staging compared with the large majority that received only
single modality staging. The improved outcomes in more
extensively staged patients was consistent in various second-
ary analyses (e.g., stage specific and lung cancer specific
survival) that were aimed at uncovering an artifactual reason
for the difference. Furthermore, the dose-response nature of
the data suggests the effect is real.
In a comprehensive review of the literature on the effect
of volume and specialization on the quality of cancer care,
Hillner et al.6 came to the conclusion that “an extensive,
consistent literature . . . supports a volume-outcome relation-
ship.” Furthermore, “across studies, the benefit from care at
high-volume centers exceeds the benefits from break-through
treatments.” The effect of better staging reported by Farjah et al.
greatly exceed the benefits with respect to treatment observed in
the review by Hillner et al., and in fact, are approximately 5 to
10 times larger than recent benefits touted as major advances in
lung cancer, such as adjuvant chemotherapy for early stage or
targeted therapy for stage IV NSCLC.7,8
How should quality in staging of NSCLC be defined?
Although the study points out just how important this is, it
does not allow this to be defined. Such a definition requires
translation of data from a large number of patients to a single
institution or practitioner, and in fact to an individual patient.
However, whether 1, 2, 3 or more staging modalities are
appropriate depends on many factors and does not easily lend
itself to a simple formula by which the quality of care for an
individual patient can be judged. In fact, it is difficult to even
speculate on exactly how often the observed staging was
inappropriate according to current guidelines.
Why was the extent of staging so limited? A major
limitation of this avenue of investigation of large databases is
that there is insufficient detail to drill down and establish the
true causes. One can speculate based on this and other
studies, however. Perhaps it is related to the fact that a major
proportion of thoracic surgery in the United States is done by
surgeons whose major focus is in other areas (either cardiac
surgeons or general surgeons). Perhaps it is related to the fact
that a large proportion of patients with lung cancer are treated
at institutions that treat only a limited number of patients per
year. This does not mean that these physicians and institu-
tions are not interested in providing their patients with good
care. It may be related to lack of access to staging procedures.
Or it may be related to an insufficient understanding of the
indications for and importance of thorough staging.
The ever-increasing fund of knowledge is making it
harder, in fact impossible, for any one person to be fully
aware of the data, and drives us to a system involving
subspecialists, and ideally multidisciplinary teams of subspe-
cialists in a particular disease such as lung cancer. People and
institutions that have to deal with caring for a variety of
patients, often only a few of each kind per year, have inherent
difficulty in staying abreast of the field in all areas. Guide-
lines that promote evidence-based standards have proliferated
widely during the past decade to address this issue. However,
research has shown that they have limited impact when they
are developed externally and disseminated as published ma-
terial.9 Guidelines must be translated locally into standard
evaluation and treatment policies before they have significant
impact This study supports this conclusion.
The study by Farjah et al. poignantly points out that if
we want to improve the outcomes for patients with lung
cancer, we have to address issues related to the quality of
care, and not focus only on finding new medical “break-
throughs.” But what exactly should we be doing? Clearly, we
need further work to define appropriate metrics of quality of
care. But the main issue is not imposing metrics, but in being
able to disseminate expertise. It is unrealistic, and in fact
logistically impossible for most patients with lung cancer to
be seen at a few highly specialized institutions. We must find
ways in which subspecialists can effectively interface with
generalists at other institutions. An effective interface should
improve the level of expertise, the thoroughness in evaluation
and development of treatment plans, and thereby the out-
comes for all patients at the participating sites.
This is difficult, because our health care system fosters
competition and distrust. Health policy makers should focus
on changing our systems to reward collaboration. If we
merely impose a simple quality metric, we will probably have
limited success because we have not addressed the underlying
causes of the problem.
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